<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">Am J Gastroenterol</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>The American journal of gastroenterology</journal-title></journal-title-group><issn pub-type="ppub">0002-9270</issn><issn pub-type="epub">1572-0241</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10841309</article-id><article-id pub-id-type="pmcid-ver">PMC10841309.319</article-id><article-id pub-id-type="pmcaid">10841309</article-id><article-id pub-id-type="pmcaiid">10841309</article-id><article-id pub-id-type="manuscript-id">NIHMS1918058</article-id><article-id pub-id-type="pmid">37463438</article-id><article-id pub-id-type="doi">10.14309/ajg.0000000000002412</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1918058</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1918058</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity Matched Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Barnes</surname><given-names initials="EL">Edward L.</given-names></name><degrees>MD, MPH</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Desai</surname><given-names initials="A">Aakash</given-names></name><degrees>MD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kochhar</surname><given-names initials="GS">Gursimran S.</given-names></name><degrees>MD</degrees><xref rid="A5" ref-type="aff">5</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC</aff><aff id="A2"><label>2</label>Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC</aff><aff id="A3"><label>3</label>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC</aff><aff id="A4"><label>4</label>Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA</aff><aff id="A5"><label>5</label>Division of Gastroenterology, Hepatology &amp; Nutrition, Allegheny Health Network, Pittsburgh, Pennsylvania, USA</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">
<underline>Specific author contributions:</underline>
</p><p id="P2">ELB: study planning, oversight of the study, interpretation of the data, writing of the initial draft of the manuscript, critical revision of the manuscript.</p><p id="P3">AD: study planning, oversight of the study, data acquisition, conduction of the study and statistical analysis, interpretation of the data, critical revision of the manuscript.</p><p id="P4">GSK: study planning, oversight of the study, data acquisition, interpretation of the data, critical revision of the manuscript.</p></fn><corresp id="CR1"><underline>Corresponding Author:</underline> Edward L. Barnes, MD, MPH, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Campus Box #7080, 130 Mason Farm Road, Chapel Hill, NC 27599-7080, Phone: 919-962-3112, Fax: 919-966-6842, <email>edward_barnes@med.unc.edu</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P30">Potential Competing Interests:</p><p id="P31">Edward L. Barnes has served as a consultant for Bristol-Meyers Squibb and Target RWE.</p><p id="P32">Aakash Desai: None</p><p id="P33">Gursimran Kochhar: Advisor Board: Lilly USA, CorVetas research foundation, GIE medical; Speaker: Lilly Pharma; Consultant: Pentax Endoscopy, Boston Scientific; Stock Options: DigbiHealth</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>19</day><month>7</month><year>2023</year></pub-date><volume>118</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">455061</issue-id><fpage>1989</fpage><lpage>1996</lpage><pub-history><event event-type="nihms-submitted"><date><day>27</day><month>07</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-01 00:25:14.317"><day>01</day><month>05</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1918058.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" xlink:title="article-commentary" journal-id="Am J Gastroenterol" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11068483"><article-title>Response to Lin and Wei</article-title><volume>119</volume><issue>5</issue><date><day>18</day><month>1</month><year>2024</year></date><fpage>996</fpage><lpage>997</lpage><source>The American journal of gastroenterology</source><pub-id pub-id-type="pmcid">PMC11068483</pub-id><pub-id pub-id-type="pmid">38534001</pub-id></related-article><abstract id="ABS1"><sec id="S1"><title>Objectives:</title><p id="P5">There is minimal evidence regarding the comparative effectiveness of individual antibiotics in the treatment of pouchitis. We sought to evaluate the comparative effectiveness of ciprofloxacin monotherapy, metronidazole monotherapy, and combination therapy (ciprofloxacin and metronidazole) in the treatment of an initial episode of pouchitis after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC).</p></sec><sec id="S2"><title>Methods:</title><p id="P6">We performed a retrospective cohort study in TriNetX, a global federated research network of electronic health records. Primary outcomes were failure of initial antibiotic therapy and the development of recurrent pouchitis in the first 12 months after an initial episode of pouchitis. One-to-one propensity score matching (PSM) was performed for age, sex, race, primary sclerosing cholangitis, nicotine dependence, obesity, and previous exposure to tumor necrosis factor inhibitors between the cohorts.</p></sec><sec id="S3"><title>Results:</title><p id="P7">Among 271 patients who developed pouchitis (mean age at IPAA 35.8 years, male sex 57%) and were treated with ciprofloxacin, metronidazole, or combination therapy, 190 (70%) developed recurrent pouchitis. After PSM, there was no significant difference in the odds of early relapse or non-response with ciprofloxacin compared to metronidazole monotherapy (aOR 0.56, 95% CI 0.23&#8211;1.34) or when either monotherapy was compared to combination therapy. There was also no significant difference in odds of recurrent pouchitis when comparing patients treated with ciprofloxacin to metronidazole monotherapy (adjusted OR [aOR] 0.86, 95% CI 0.40&#8211;1.84) or either monotherapy to combination therapy.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P8">In this retrospective cohort study, we demonstrated no significant difference in the real-world effectiveness of ciprofloxacin, metronidazole, or combination therapy for the initial episode of pouchitis.</p></sec></abstract><kwd-group><kwd>comparative effectiveness</kwd><kwd>real-world effectiveness</kwd><kwd>pouchitis</kwd><kwd>ileal pouch-anal anastomosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>